Please note that we charge an extra fee for prenatal analysis.
Prenatal Testing Is Given the Highest Priority at CENTOGENE
Prenatal genetic testing for congenital and early onset diseases. Early and accurate identification of disease-causing mutations in "at-risk" families before birth. All monogenic diseases can be detected, even at the early stages of pregnancy.
The choice of the appropriate testing strategy and a quick response are key factors to minimize the stress.
This is why CENTOGENE offers a turnaround time of ten business days for most prenatal analyses (known variants, deletion/duplication analysis, single gene sequencing) and of less than 15 business days for NGS (next generation sequencing) analyses (CentoXome®, CentoGenome® and CentoArray®). In addition, our medical experts are always available for your support before, during and after the analysis.
Why Choose CENTOGENE?
Distinctive product offering centered around high-quality genetic testing
Strong presence in and access to countries with a high prevalence of rare diseases
CentoCard provides easy logistics for central testing
Rare disease-centric Bio/Databank generates best-in-class medical insights
Deep expertise in rare, metabolic, and neurodegenerative diseases, as well as multiomics enables better diagnostics
- Chorionic villi
- Amniotic fluid
- Fetal DNA
- Cord blood (for late pregnancies) as possible material
You have the option to send us tubes with already cultivated cells. Alternatively, we offer CentoCulture®, our cell cultivation service.
Please always contact us prior to every prenatal sample sending to prevent transport delays and to allow us to give the analysis top priority. Please provide the following mandatory information :
- Logistics tracking number of sample shipment
- Requested analysis
- Physician's contact information
All prenatal cases are specifically assigned to our dedicated prenatal team who takes the utmost individual care.
Logistic and Communication Manager
+49 381 80113 663
Proof-of-Principle Rapid Noninvasive Prenatal Diagnosis of Autosomal Recessive Founder Mutations
Proof-of-principle rapid noninvasive prenatal diagnosis of autosomal recessive founder mutations. Ten parental alleles in eight unrelated fetuses were diagnosed successfully based on the noninvasive […]
Validation of a Semiconductor Next-Generation Sequencing Assay for the Clinical Genetic Screening of CFTR
Genetic testing for cystic fibrosis and CFTR-related disorders mostly relies on laborious molecular tools that use Sanger sequencing to scan for mutations in the CFTR gene. We have explored a more […]
A Novel Mutation Causing 17-β-Hydroxysteroid
This is the first case report in Oman and the Gulf region of a 17-β-hydroxysteroid dehydrogenase type 3 (17-β-HSD3) deficiency with a novel mutation in the HSD17B3 gene that has not been previously […]
研討會中，我們論述了 CENTOGENE 產前篩查選項，以及產前檢測如何在孕週期時發揮關鍵作用，快速尋找答案。
Reproductive Health and Prenatal Genetic Testing
Throughout the CentoTalk, Clarice Loh provides a detailed overview of CENTOGENE’s prenatal screening options and how prenatal testing plays an essential role in facilitating early answers when […]
What You Need to Know about Carrier Screening
Carrier screening is a predictive genetic testing, designed for future parents. Would you like to learn more and understand it better? Watch our recorded webinar about CentoScreen®: "What you need to […]